Overview

Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer

Status:
Terminated
Trial end date:
2021-03-03
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to look at the safety and side effects of combining the drug pembrolizumab with imiquimod, GM-CSF, and cryotherapy to treat breast cancer that includes skin lesions.
Phase:
Phase 1
Details
Lead Sponsor:
Washington University School of Medicine
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Imiquimod
Pembrolizumab
Sargramostim